Clinical Trials

32 enrolled

Liposarcoma, Sarcoma, Perivascular Epithelioid Cell Neoplasms

NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04214067 2026-05-13

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Phase 3 Active not recruiting

164 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinosarcoma

NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1 Recruiting

15 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT06898970 2026-05-08

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

18 enrolled

Hemangiosarcoma

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03349450 2026-05-06

SPiReL

Phase 3 Active not recruiting

25 enrolled 18 charts

LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04483778 2026-04-28

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

68 enrolled

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05156268 2026-04-27

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

26 enrolled

GynecologicSarcoma

Endometrial Carcinosarcoma

NCT03414229 2026-04-23

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

30 enrolled 11 charts

NCT04332874 2026-04-23

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

30 enrolled

Sarcoma, Dermatofibrosarcoma, Sarcoma, Alveolar Soft Part, Histiocytoma, Malignant Fibrous

NCT05732831 2026-04-21

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

GastrointestinalOther solid neoplasmSarcomaThoracic

225 enrolled

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT07283731 2026-04-17

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

20 enrolled

Neoplasm Metastasis, Sarcoma

NCT07301268 2026-04-08

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

36 enrolled

Astrocytoma, Glioblastoma, Gliosarcoma

NCT03197506 2026-03-25

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

52 enrolled 19 charts

Glioblastoma, Gliosarcoma

NCT04670679 2026-03-25

FLAGSHP-1

GastrointestinalHead & NeckSarcoma

90 enrolled

Squamous Cell Carcinoma of Head and Neck, Chordoma, Neoplasm Metastasis, Neoplasms, Noonan Syndrome, Colorectal Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03123276 2026-02-13

GEMMK

Phase 1/2 Completed

25 enrolled 15 charts

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Phase 2 Suspended

18 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

11 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

28 enrolled

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT05846724 2026-01-22

PULSAR

Phase 2 Withdrawn

Sarcoma, Kaposi

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

54 enrolled

Glioblastoma, Gliosarcoma

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

BreastDermatologicSarcoma

14 enrolled

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT02406781 2025-12-10

PEMBROSARC

129 enrolled 17 charts

Leiomyosarcoma, Sarcoma, Osteosarcoma

NCT06128863 2025-12-08

EFTISARC-NEO

40 enrolled

DermatologicHead & NeckSarcoma

NCT05859074 2025-12-03

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Phase 1 Recruiting

56 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Hemangiosarcoma, Melanoma, Neoplasm Metastasis, Neoplasms, Paget Disease, Extramammary, Sarcoma, Kaposi, Skin Neoplasms, Carcinoma, Merkel Cell, Adenocarcinoma, Sebaceous, Carcinoma, Skin Appendage

NCT06116578 2025-12-01

NeoSarc

Phase 2 Withdrawn

BreastDermatologicSarcomaThoracic

Liposarcoma, Neoplasms, Sarcoma

NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Phase 1/2 Terminated

31 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03069378 2025-10-29

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

41 enrolled 8 charts

Neoplasm Metastasis, Sarcoma

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Other solid neoplasmSarcoma

610 enrolled

Advanced Solid Tumors

NCT04370587 2025-10-08

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

DermatologicHead & NeckSarcoma

30 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Melanoma, Sarcoma

NCT05488366 2025-09-22

Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma

Phase EARLY_PHASE1 Active not recruiting

9 enrolled

NCT03899805 2025-08-28

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

57 enrolled 14 charts

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT02337686 2025-08-15

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

18 enrolled 12 charts

Phase 1/2 Active not recruiting

Glioblastoma, Gliosarcoma

NCT03611868 2025-08-07

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

230 enrolled

DermatologicSarcoma

Uveal Melanoma, Melanoma, Neurofibrosarcoma

NCT05679921 2025-07-16

Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma

116 enrolled

Phase 1/2 Active not recruiting

NCT04140526 2025-05-23

PRESERVE-001

733 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03058289 2025-02-27

IT-01

Phase 1/2 Completed

111 enrolled 21 charts

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT06494787 2025-02-24

SOC-2320

Phase 2 Withdrawn

NCT06794645 2025-01-27

Pembrolizumab and Pemetrexed for Progressive Chordoma

21 enrolled

Chordoma

NCT03009058 2024-11-25

MODULATE

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

DermatologicGastrointestinalGenitourinarySarcoma

358 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT03126591 2024-10-23

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Phase 1 Completed

41 enrolled 19 charts